If you’re pursuing novel drug discovery targets with sparse or fragmented data, don’t miss our upcoming webinar on June 11th (1:30 PM EST) to learn how Avammune overcame this challenge across multiple therapeutic modalities to progress early design concepts through to trial‑stage candidates.
The session will focus on the practical decisions, workflows, and lessons learned along the way.
What you’ll learn:
- What actually works when pursuing novel targets with limited data
- Why conventional generative AI fell short in new chemical space
- How to evaluate conventional AI and computational approaches
- Using Cresset for de novo design without large datasets
- Advancing from concept to trial-stage candidate (canine oncology)
- Building modality-agnostic strategies with computational chemistry
This event is being hosted by our partners 20/15 Visioneers